Vinod BalachandranMD

797 posts

Vinod BalachandranMD banner
Vinod BalachandranMD

Vinod BalachandranMD

@TheVinodLab

Founding Director Olayan Center for Cancer Vaccines @MSKCancerCenter | Cancer Surgeon-Scientist | Pancreas cancer | Cancer immunology | 2x dad, 2x ironman

New York, NY Katılım Haziran 2017
136 Takip Edilen5.1K Takipçiler
Vinod BalachandranMD
Vinod BalachandranMD@TheVinodLab·
This is why we do the work! We’re hopeful that we can build on this progress and allow more patients to access these promising treatments.
Memorial Sloan Kettering Cancer Center@MSKCancerCenter

Donna was diagnosed with pancreatic cancer at age 66 when she and her husband were visiting one of their daughters in Australia. When they returned to the U.S., they immediately came to MSK for care, where she learned she was eligible for an investigational vaccine trial, to prevent pancreatic cancer from returning after surgery. MSK hepatopancreatobiliary surgeon Dr. @Jeffrey_Drebin, physician-scientist @TheVinodLab, and medical oncologist @EileenMOReilly walked Donna through each step. “They described how they would take part of my tumor to make a personalized vaccine, and it sounded amazing,” Donna says. “My husband and I had a moment of concern about delaying chemotherapy, but all the doctors made me feel so comfortable that we took the leap of faith and said, ‘Go for it.’” Over the next few months, Donna received an immunotherapy drug and eight doses of the vaccine, followed by chemotherapy, and then a final vaccine dose. Today, Donna is 72 and recently celebrated her 50th anniversary with her husband in Sicily and spends as much time as she can with her daughters and six grandchildren. Learn more about this clinical trial, presented at the 2026 American Association for Cancer Research Annual Meeting: bit.ly/3QuIiaL #AACR26

English
27
93
935
52.6K
Vinod BalachandranMD retweetledi
AACR
AACR@AACR·
Eight of 16 patients in a clinical trial of an investigational mRNA vaccine for pancreatic cancer @MSKCancerCenter had dramatic immune responses. The study, which was featured on @CNNhealth, was presented at the AACR Annual Meeting 2026. brnw.ch/21x1Lnb @CNN #AACR26
English
1
5
22
3.7K
Vinod BalachandranMD retweetledi
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center@MSKCancerCenter·
🚨 An experimental, personalized vaccine using #mRNA to prevent #pancreaticcancer from returning after surgery continues to show promise in a small, 16-person patient group. New results from a phase 1 clinical trial, being presented at #AACR26, show that nearly 90% of people whose immune systems responded to the vaccine were still alive six years later. “These early results show this new immunotherapy approach has the potential to be groundbreaking for one of the deadliest cancers,” says MSK physician-scientist Dr. Vinod Balachandran (@TheVinodLab), the trial’s principal investigator and Director of The Olayan Center for Cancer Vaccines. Learn more about these findings: bit.ly/3QuIiaL @AACR
Memorial Sloan Kettering Cancer Center tweet media
English
22
165
622
40.5K
Philipp S. Holstein
Philipp S. Holstein@PSHolstein·
Das ist phantastisch. Personalisierter mRNA-Impfstoff gegen Bauchspeicheldrüsenkrebs. 3 Jahre später die Hälfte der Geimpften noch immer rückfallfrei. nature.com/articles/s4158… Die Folgestudie erscheint in den nächsten Tagen und man hört, dass die Ergebnisse nicht enttäuschen! Aber Moment: 2019? Wurde damals also ein laut Kritikern nie vor 2021 am Menschen erprobtes Verfahren erfolgreich in einer klinischen Studie genutzt? So wie auch 2015? nature.com/articles/s4158… Und 2004? pubmed.ncbi.nlm.nih.gov/19609242/ Und 1999? clinicaltrials.gov/study/NCT00004… Seltsam.
Deutsch
63
598
2.5K
59.9K
Jonathan Reiner
Jonathan Reiner@JReinerMD·
Long term follow up of a phase 1 trial of an mRNA tumor vaccine shows that 7/8 patients with pancreatic cancer, who mounted an immune response to the vaccine, are still alive 6 years later. This is breathtaking data and shows the promise of mRNA vaccines. nbcnews.com/health/cancer/…
English
164
2.4K
9.2K
669.6K
Vinod BalachandranMD retweetledi
Ian Weissman, DO
Ian Weissman, DO@DrIanWeissman·
Pancreatic cancer mRNA vaccine shows lasting results in an early trial. Scientists caution that more research is needed, but nearly all of the patients who responded to the personalized vaccine are still alive six years later. nbcnews.com/health/cancer/…
English
516
5.8K
26.2K
5.6M
Dr Danish
Dr Danish@operationdanish·
They Said Pancreatic Cancer Was Immune to Immunotherapy. They Were Wrong. Donna Gustafson went to an Australian ER thinking she was jet-lagged. She left with a pancreatic cancer diagnosis. Less than 13% of patients survive five years. There is no routine screening. By the time it shows up, it has usually already won. That was 2026. She just climbed Mount Etna to celebrate her 50th wedding anniversary. Gustafson was the first person ever vaccinated against pancreatic cancer, using a personalized mRNA vaccine built from her own tumor’s genetic material. Six years later, seven of eight patients who mounted an immune response are still alive. For decades, scientists believed pancreatic cancer was immune to immunotherapy. They were asking the wrong question. The vaccine didn’t change the biology. It changed the timing. That’s usually how breakthroughs work. Quietly. Then all at once.
Dr Danish tweet media
English
35
191
987
79.5K
Vinod BalachandranMD retweetledi
Let's Win Pancreatic Cancer 💜
Let's Win Pancreatic Cancer 💜@letswinpc·
Could a vaccine prevent pancreatic cancer from returning after surgery? bit.ly/3OGtENb In this episode of #PancChat, host Alisyn Camerota talks with @TheVinodLab about mRNA and other promising vaccine approaches — and what early results are showing.
English
2
5
14
2K
Chrysothemis Brown
Chrysothemis Brown@themis_brown·
Very happy to share our new study defining the ontogeny of Thetis cells and the developmental cues that shape their early-life wave of differentiation. nature.com/articles/s4158… Beautiful work led by exceptional @HHMI Gilliam fellow @YoselinAPI and @MSK postdoc Tyler Park 🧵 1/
English
10
21
103
12.7K
Vinod BalachandranMD retweetledi
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center@MSKCancerCenter·
Over the last decade, computational oncologist Dr. @bengrbm has tried to shed light on the innate immune system and how it affects cancer cells as they evolve. One important aspect is a phenomenon called “viral mimicry,” caused by repetitive DNA sequences. Now Dr. Greenbaum’s lab, in collaboration with an international team of researchers, has developed a mathematical model to quantify viral mimicry based on methods from statistical physics, machine learning, and the dynamics of evolution. “A better understanding of what activates the innate immune system can help us figure out how to improve immunotherapies,” says Dr. Greenbaum. Learn more about this research: bit.ly/4h1BjPG
Memorial Sloan Kettering Cancer Center tweet media
English
0
4
16
9K
Vinod BalachandranMD retweetledi
Benjamin D. Greenbaum
Benjamin D. Greenbaum@bengrbm·
Thank you @MSKCancerCenter for highlighting our work on #viralmimicry in our genome, its evolution, the selective forces on it, and its potential role in cancer. A years long collaborative effort with @sunsiyu1 @stephen_martis @decarvalho_lab @petr_sulc & many great colleagues!
Memorial Sloan Kettering Cancer Center@MSKCancerCenter

Over the last decade, computational oncologist Dr. @bengrbm has tried to shed light on the innate immune system and how it affects cancer cells as they evolve. One important aspect is a phenomenon called “viral mimicry,” caused by repetitive DNA sequences. Now Dr. Greenbaum’s lab, in collaboration with an international team of researchers, has developed a mathematical model to quantify viral mimicry based on methods from statistical physics, machine learning, and the dynamics of evolution. “A better understanding of what activates the innate immune system can help us figure out how to improve immunotherapies,” says Dr. Greenbaum. Learn more about this research: bit.ly/4h1BjPG

English
0
1
16
1.8K

Keşfet

@MSKCancerCenter @cnnhealth @CNN @Noahpinion @AACR @PSHolstein @JReinerMD @DrIanWeissman